Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Primary care provider adherence to reproductive healthcare guidelines in adolescents and young adults with disabilities: A retrospective matched cohort study1.

Roden RC, Oholendt K, Lange H, Noritz G, Bonny AE.

J Pediatr Rehabil Med. 2019;12(3):317-324. doi: 10.3233/PRM-180589.

PMID:
31476181
2.

Incorporation of RG1 epitope into HPV16L1-VLP does not compromise L1-specific immunity.

Schellenbacher C, Huber B, Skoll M, Shafti-Keramat S, Roden RBS, Kirnbauer R.

Vaccine. 2019 Jun 12;37(27):3529-3534. doi: 10.1016/j.vaccine.2019.05.011. Epub 2019 May 27.

PMID:
31147274
3.

Infectivity of murine papillomavirus in the surgical byproducts of treated tail warts.

Best SR, Esquivel D, Mellinger-Pilgrim R, Roden RBS, Pitman MJ.

Laryngoscope. 2019 May 1. doi: 10.1002/lary.28026. [Epub ahead of print]

PMID:
31041820
4.

Opportunities to improve immune-based prevention of HPV-associated cancers.

Stern PL, Roden RB.

Papillomavirus Res. 2019 Jun;7:150-153. doi: 10.1016/j.pvr.2019.04.010. Epub 2019 Apr 11.

5.

The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies.

Button B, Croessmann S, Chu D, Rosen DM, Zabransky DJ, Dalton WB, Cravero K, Kyker-Snowman K, Waters I, Karthikeyan S, Christenson ES, Donaldson J, Hunter T, Dennison L, Ramin C, May B, Roden R, Petry D, Armstrong DK, Visvanathan K, Park BH.

Breast Cancer Res Treat. 2019 Apr;174(2):401-412. doi: 10.1007/s10549-018-05087-7. Epub 2018 Dec 17.

PMID:
30560461
6.

Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study.

Ramin C, May BJ, Roden RBS, Orellana MM, Hogan BC, McCullough MS, Petry D, Armstrong DK, Visvanathan K.

Breast Cancer Res. 2018 Nov 13;20(1):134. doi: 10.1186/s13058-018-1061-4.

7.

A Bayesian design for phase I cancer therapeutic vaccine trials.

Wang C, Rosner GL, Roden RBS.

Stat Med. 2019 Mar 30;38(7):1170-1189. doi: 10.1002/sim.8021. Epub 2018 Oct 25.

8.

Epithelial boost enhances antigen expression by vaccinia virus for the generation of potent CD8+ T cell-mediated antitumor immunity following DNA priming vaccination.

Qiu J, Peng S, Ma Y, Yang A, Farmer E, Cheng MA, Roden RBS, Wu TC, Chang YN, Hung CF.

Virology. 2018 Dec;525:205-215. doi: 10.1016/j.virol.2018.09.019. Epub 2018 Oct 5.

9.

Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer.

Anchoori RK, Jiang R, Peng S, Soong RS, Algethami A, Rudek MA, Anders N, Hung CF, Chen X, Lu X, Kayode O, Dyba M, Walters KJ, Roden RBS.

ACS Omega. 2018 Sep 30;3(9):11917-11929. doi: 10.1021/acsomega.8b01479. Epub 2018 Sep 27.

10.

Production and characterization of a novel HPV anti-L2 monoclonal antibody panel.

Bywaters SM, Brendle SA, Biryukov J, Wang JW, Walston J, Milici J, Roden RB, Meyers C, Christensen ND.

Virology. 2018 Nov;524:106-113. doi: 10.1016/j.virol.2018.08.017. Epub 2018 Aug 28.

PMID:
30170240
11.

Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus.

Wang JW, Wu WH, Huang TC, Wong M, Kwak K, Ozato K, Hung CF, Roden RBS.

J Virol. 2018 Jul 17;92(15). pii: e00572-18. doi: 10.1128/JVI.00572-18. Print 2018 Aug 1.

12.

Opportunities and challenges for human papillomavirus vaccination in cancer.

Roden RBS, Stern PL.

Nat Rev Cancer. 2018 Apr;18(4):240-254. doi: 10.1038/nrc.2018.13. Epub 2018 Mar 2. Review.

13.

Detection and localization of surgically resectable cancers with a multi-analyte blood test.

Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, Douville C, Javed AA, Wong F, Mattox A, Hruban RH, Wolfgang CL, Goggins MG, Dal Molin M, Wang TL, Roden R, Klein AP, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Vogelstein JT, Browne JD, Schoen RE, Brand RE, Tie J, Gibbs P, Wong HL, Mansfield AS, Jen J, Hanash SM, Falconi M, Allen PJ, Zhou S, Bettegowda C, Diaz LA Jr, Tomasetti C, Kinzler KW, Vogelstein B, Lennon AM, Papadopoulos N.

Science. 2018 Feb 23;359(6378):926-930. doi: 10.1126/science.aar3247. Epub 2018 Jan 18.

14.

Severe Sepsis and Acute Myocardial Dysfunction in an Adolescent with Chlamydia Trachomatis Pelvic Inflammatory Disease: A Case Report.

Morgan AM, Roden RC, Matson SC, Wallace GM, Lange HLH, Bonny AE.

J Pediatr Adolesc Gynecol. 2018 Apr;31(2):143-145. doi: 10.1016/j.jpag.2017.10.004. Epub 2017 Oct 13.

PMID:
29037929
15.

The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis.

Ahn J, Bishop JA, Roden RBS, Allen CT, Best SRA.

Laryngoscope. 2018 Jan;128(1):E27-E32. doi: 10.1002/lary.26847. Epub 2017 Sep 22.

16.

Prophylactic immunization with human papillomavirus vaccines induces oral immunity in mice.

Ahn J, Peng S, Hung CF, Roden RBS, Best SR.

Laryngoscope. 2018 Jan;128(1):E16-E20. doi: 10.1002/lary.26772. Epub 2017 Sep 4.

17.

Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.

Jiang RT, Yemelyanova A, Xing D, Anchoori RK, Hamazaki J, Murata S, Seidman JD, Wang TL, Roden RBS.

J Ovarian Res. 2017 Aug 7;10(1):53. doi: 10.1186/s13048-017-0347-y.

18.

Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes.

Kalnin K, Chivukula S, Tibbitts T, Yan Y, Stegalkina S, Shen L, Cieszynski J, Costa V, Sabharwal R, Anderson SF, Christensen N, Jagu S, Roden RBS, Kleanthous H.

Vaccine. 2017 Sep 5;35(37):4942-4951. doi: 10.1016/j.vaccine.2017.07.086. Epub 2017 Aug 1.

19.

Immunologic responses to a novel DNA vaccine targeting human papillomavirus-11 E6E7.

Ahn J, Peng S, Hung CF, Roden RBS, Wu TC, Best SR.

Laryngoscope. 2017 Dec;127(12):2713-2720. doi: 10.1002/lary.26737. Epub 2017 Jul 17.

20.

Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease.

Shah AA, Rosen A, Hummers LK, May BJ, Kaushiva A, Roden RBS, Armstrong DK, Wigley FM, Casciola-Rosen L, Visvanathan K.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):71-74. Epub 2017 Jun 19.

21.

Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection.

Jiang RT, Wang JW, Peng S, Huang TC, Wang C, Cannella F, Chang YN, Viscidi RP, Best SRA, Hung CF, Roden RBS.

J Virol. 2017 Jul 12;91(15). pii: e00699-17. doi: 10.1128/JVI.00699-17. Print 2017 Aug 1.

22.

An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors.

Li QK, Shah P, Tian Y, Hu Y, Roden RBS, Zhang H, Chan DW.

Clin Proteomics. 2017 May 10;14:16. doi: 10.1186/s12014-017-9152-2. eCollection 2017.

23.

Developments in L2-based human papillomavirus (HPV) vaccines.

Schellenbacher C, Roden RBS, Kirnbauer R.

Virus Res. 2017 Mar 2;231:166-175. doi: 10.1016/j.virusres.2016.11.020. Epub 2016 Nov 23. Review.

24.

The Replicative Consequences of Papillomavirus E2 Protein Binding to the Origin Replication Factor ORC2.

DeSmet M, Kanginakudru S, Rietz A, Wu WH, Roden R, Androphy EJ.

PLoS Pathog. 2016 Oct 4;12(10):e1005934. doi: 10.1371/journal.ppat.1005934. eCollection 2016 Oct.

25.

RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.

Soong RS, Anchoori RK, Yang B, Yang A, Tseng SH, He L, Tsai YC, Roden RB, Hung CF.

Oncotarget. 2016 Oct 18;7(42):68489-68502. doi: 10.18632/oncotarget.12095.

26.

Immunizing against Anogenital Cancer: HPV Vaccines.

Pogoda CS, Roden RB, Garcea RL.

PLoS Pathog. 2016 May 19;12(5):e1005587. doi: 10.1371/journal.ppat.1005587. eCollection 2016 May. Review. No abstract available.

27.

Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease.

Peng S, Qiu J, Yang A, Yang B, Jeang J, Wang JW, Chang YN, Brayton C, Roden RBS, Hung CF, Wu TC.

Cell Biosci. 2016 Feb 25;6:16. doi: 10.1186/s13578-016-0080-z. eCollection 2016.

28.

The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression.

Randles L, Anchoori RK, Roden RB, Walters KJ.

J Biol Chem. 2016 Apr 15;291(16):8773-83. doi: 10.1074/jbc.M115.694588. Epub 2016 Feb 23.

29.

Progress and prospects for L2-based human papillomavirus vaccines.

Jiang RT, Schellenbacher C, Chackerian B, Roden RB.

Expert Rev Vaccines. 2016 Jul;15(7):853-62. doi: 10.1586/14760584.2016.1157479. Epub 2016 Mar 10. Review.

30.

Case 3: Fever, Limp, and Hip and Knee Pain in a 7-year-old Boy.

Roden RC, Feingold A, Meislich D.

Pediatr Rev. 2016 Jan;37(1):45-7. doi: 10.1542/pir.2014-0078. No abstract available.

PMID:
26729783
31.

Identification of Anti-CA125 Antibody Responses in Ovarian Cancer Patients by a Novel Deep Sequence-Coupled Biopanning Platform.

Frietze KM, Roden RB, Lee JH, Shi Y, Peabody DS, Chackerian B.

Cancer Immunol Res. 2016 Feb;4(2):157-64. doi: 10.1158/2326-6066.CIR-15-0165. Epub 2015 Nov 20.

32.

Immunologic Control of Mus musculus Papillomavirus Type 1.

Wang JW, Jiang R, Peng S, Chang YN, Hung CF, Roden RB.

PLoS Pathog. 2015 Oct 23;11(10):e1005243. doi: 10.1371/journal.ppat.1005243. eCollection 2015 Oct.

33.

Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.

Sun YY, Peng S, Han L, Qiu J, Song L, Tsai Y, Yang B, Roden RB, Trimble CL, Hung CF, Wu TC.

Clin Cancer Res. 2016 Feb 1;22(3):657-69. doi: 10.1158/1078-0432.CCR-15-0234. Epub 2015 Sep 29.

34.

Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.

Jagu S, Karanam B, Wang JW, Zayed H, Weghofer M, Brendle SA, Balogh KK, Tossi KP, Roden RBS, Christensen ND.

Vaccine. 2015 Oct 13;33(42):5553-5563. doi: 10.1016/j.vaccine.2015.09.005. Epub 2015 Sep 15.

35.

Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.

Wu WH, Alkutkar T, Karanam B, Roden RB, Ketner G, Ibeanu OA.

Virol J. 2015 Sep 11;12:140. doi: 10.1186/s12985-015-0364-7.

36.

Production of Furin-Cleaved Papillomavirus Pseudovirions and Their Use for In Vitro Neutralization Assays of L1- or L2-Specific Antibodies.

Wang JW, Matsui K, Pan Y, Kwak K, Peng S, Kemp T, Pinto L, Roden RB.

Curr Protoc Microbiol. 2015 Aug 3;38:14B.5.1-26. doi: 10.1002/9780471729259.mc14b05s38.

37.

Weight change in breast cancer survivors compared to cancer-free women: a prospective study in women at familial risk of breast cancer.

Gross AL, May BJ, Axilbund JE, Armstrong DK, Roden RB, Visvanathan K.

Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1262-9. doi: 10.1158/1055-9965.EPI-15-0212. Epub 2015 Jul 15.

38.

Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination.

Yang B, Yang A, Peng S, Pang X, Roden RB, Wu TC, Hung CF.

Cell Biosci. 2015 Jun 25;5:35. doi: 10.1186/s13578-015-0025-y. eCollection 2015.

39.

ADRM1-amplified metastasis gene in gastric cancer.

Fejzo MS, Anderson L, Chen HW, Anghel A, Zhuo J, Anchoori R, Roden R, Slamon DJ.

Genes Chromosomes Cancer. 2015 Aug;54(8):506-515. doi: 10.1002/gcc.22262. Epub 2015 Jun 6.

PMID:
26052681
40.

Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.

Wang JW, Jagu S, Wu WH, Viscidi RP, Macgregor-Das A, Fogel JM, Kwak K, Daayana S, Kitchener H, Stern PL, Gravitt PE, Trimble CL, Roden RB.

Clin Vaccine Immunol. 2015 Jul;22(7):806-16. doi: 10.1128/CVI.00799-14. Epub 2015 May 13.

41.

Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells.

Vogel RI, Coughlin K, Scotti A, Iizuka Y, Anchoori R, Roden RB, Marastoni M, Bazzaro M.

Oncotarget. 2015 Feb 28;6(6):4159-70.

42.

Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer.

Peng S, Wang JW, Karanam B, Wang C, Huh WK, Alvarez RD, Pai SI, Hung CF, Wu TC, Roden RB.

PLoS One. 2015 Jan 5;10(1):e116389. doi: 10.1371/journal.pone.0116389. eCollection 2015.

43.

Immunoprevention of human papillomavirus-associated malignancies.

Wang JW, Hung CF, Huh WK, Trimble CL, Roden RB.

Cancer Prev Res (Phila). 2015 Feb;8(2):95-104. doi: 10.1158/1940-6207.CAPR-14-0311. Epub 2014 Dec 8. Review.

44.

Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer.

Erickson BK, Kinde I, Dobbin ZC, Wang Y, Martin JY, Alvarez RD, Conner MG, Huh WK, Roden RB, Kinzler KW, Papadopoulos N, Vogelstein B, Diaz LA Jr, Landen CN Jr.

Obstet Gynecol. 2014 Nov;124(5):881-5. doi: 10.1097/AOG.0000000000000484.

45.

GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility.

Banet N, Gown AM, Shih IeM, Kay Li Q, Roden RB, Nucci MR, Cheng L, Przybycin CG, Nasseri-Nik N, Wu LS, Netto GJ, Ronnett BM, Vang R.

Am J Surg Pathol. 2015 Jan;39(1):101-8. doi: 10.1097/PAS.0000000000000315.

46.

Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.

Wang JW, Jagu S, Wang C, Kitchener HC, Daayana S, Stern PL, Pang S, Day PM, Huh WK, Roden RB.

PLoS One. 2014 Jul 7;9(7):e101576. doi: 10.1371/journal.pone.0101576. eCollection 2014.

47.

Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.

Berg MG, Adams RJ, Gambhira R, Siracusa MC, Scott AL, Roden RB, Ketner G.

Clin Vaccine Immunol. 2014 Sep;21(9):1224-31. doi: 10.1128/CVI.00197-14. Epub 2014 Jul 2.

48.

Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFN╬│.

Soong RS, Song L, Trieu J, Knoff J, He L, Tsai YC, Huh W, Chang YN, Cheng WF, Roden RB, Wu TC, Trimble CL, Hung CF.

Clin Cancer Res. 2014 Nov 1;20(21):5456-67. doi: 10.1158/1078-0432.CCR-14-0344. Epub 2014 Jun 3.

49.

Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.

Kwak K, Jiang R, Wang JW, Jagu S, Kirnbauer R, Roden RB.

PLoS One. 2014 May 9;9(5):e97232. doi: 10.1371/journal.pone.0097232. eCollection 2014.

50.

Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.

Kalnin K, Tibbitts T, Yan Y, Stegalkina S, Shen L, Costa V, Sabharwal R, Anderson SF, Day PM, Christensen N, Schiller JT, Jagu S, Roden RB, Almond J, Kleanthous H.

Vaccine. 2014 Jun 12;32(28):3540-7. doi: 10.1016/j.vaccine.2014.04.032. Epub 2014 Apr 26.

Supplemental Content

Support Center